B
Bull
Bull · 25%NKTX
$2.37
Szenariopreis
$2.760
+0.010 (+0.36%)Zum Schluss
Loading chart…
- High
- 2.790
- Open
- 2.750
- VWAP
- 2.75
- Vol
- 430.98K
- Mkt Cap
- 412.94M
- Low
- 2.695
- Amount
- 1.18M
- EV/EBITDA, TTM
- 0.00
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
AI analysis of Nkarta Inc (NKTX)
buyNkarta Inc (NKTX) appears to be a good buy right now, trading at $2.76 with a significant year-to-date change of +47.59%. The RSI is at 69.39, indicating strong momentum, while the stock has recently seen a 32.06% increase over the last 20 days. However, the main risk is the widening net loss reported in Q2, which was $40.37 million, significantly impacting investor sentiment.
Bewertungskennzahlen
The current forward P/E ratio for Nkarta Inc (NKTX) is 0.00, compared to its 5-year average forward P/E of -3.15.
Alphio AI Price Scenarios for NKTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NKTX
Event-Zeitleiste
News
9.508-11NASDAQ.COMNkarta Reports Wider Net Loss in Q2 Financial Results
5.007-23GlobenewswireCyllene Therapeutics Appoints New Executives to Leadership Team
5.007-23NewsfilterCyllene Therapeutics Appoints New Board Members and VPs
8.506-12GlobenewswireGT Biopharma Advances NK Cell Therapy with TriKE Platform
- 8.506-12Newsfilter
GT Biopharma Advances NK Cell Therapy with TriKE Platform
NKTX FAQ — answered by Alphio AI
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Nkarta Inc (NKTX) appears to be a good buy right now, trading at $2.76 with a significant year-to-date change of +47.59%. The RSI is at 69.39, indicating strong momentum, while the stock has recently seen a 32.06% increase over the last 20 days. However, the main risk is the widening net loss reported in Q2, which was $40.37 million, significantly impacting investor sentiment.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.